NVP-BKM120 Hydrochloride: A Potent PI3K Inhibitor for Cancer Research
Discover the potential of NVP-BKM120 Hydrochloride in targeted cancer therapies and oncology research.
Get a Quote & SampleProduct Core Value
NVP-BKM120 Hydrochloride
NVP-BKM120 Hydrochloride is a potent, selective, and orally bioavailable inhibitor of class I PI3K isoforms. With significant efficacy demonstrated in preclinical models, it plays a crucial role in advancing cancer therapy research by targeting the PI3K pathway.
- Explore the potent and selective PI3K inhibitor mechanism of NVP-BKM120 Hydrochloride, a key compound for oncology drug development.
- Understand the PI3K pathway inhibitor applications in various cancer types, leveraging its ability to inhibit tumor growth in vivo.
- Learn about the efficacy of NVP-BKM120 in vivo activity, a critical factor for preclinical validation and advancing targeted cancer therapies.
- Discover the status of Buparlisib hydrochloride clinical trials, showcasing its potential as a therapeutic agent in human studies.
Advantages of NVP-BKM120 Hydrochloride
Targeted PI3K Inhibition
NVP-BKM120 Hydrochloride offers precise inhibition of PI3K isoforms, crucial for understanding and treating cancers driven by PI3K pathway dysregulation. This makes it an invaluable tool for cancer therapy research.
In Vivo Efficacy
Demonstrated antitumor activity in vivo highlights the compound's potential for clinical translation. The NVP-BKM120 in vivo activity is a key indicator of its therapeutic promise in preclinical settings.
Advancing Oncology Drug Development
As a leading PI3K inhibitor, NVP-BKM120 Hydrochloride is instrumental in drug discovery and development efforts, offering insights into novel treatment strategies for various malignancies. Its role in advancing oncology drug development is significant.
Key Applications
Oncology Research
Utilized extensively in research to elucidate the role of PI3K signaling in cancer proliferation, survival, and metastasis, supporting the development of new cancer therapy research approaches.
Pharmaceutical Intermediate
Serves as a critical intermediate in the synthesis of advanced pharmaceutical compounds, aiding in the discovery and production of novel therapeutics. The availability of high-quality pharmaceutical intermediates is vital.
Drug Discovery & Development
Empowers drug discovery programs by providing a well-characterized tool to investigate PI3K-targeted therapies, contributing to the pipeline of potential new cancer treatments. Understanding PI3K inhibitor IC50 values is key here.
Clinical Trials
Investigated in clinical trials for various cancers, demonstrating its therapeutic potential and paving the way for new treatment options. The progress of Buparlisib hydrochloride clinical trials is closely watched.